Thursday 16 February, London: The discovery of the ‘molecular switch’ that causes inflammatory bowel disease (IBD) and Celiac disease, could lead to more effective new treatments for these life-changing auto-immune conditions, according to researchers from scientists at King’s College London and University College London.
For the first time, researchers have a specific target for the treatment of these conditions by indentifying an immune molecule called T-bet as the key control point that regulates this genetic risk in specific diseases. The discovery has been published in the journal PLoS Genetics.
T-bet plays an important role in coordinating the body’s immune responses. In patients with IBD, T-bet behaves abnormally, causing the immune reaction which leads to the development of the condition.
A great deal of work has been done on the genetic predisposition to autoimmune disease over the past 10 years. However, it has been very difficult to develop effective treatments because a large number of genes each make a very small contribution to the development of these diseases.
“Our research outlines a specific focus for the development of new treatments for inflammatory bowel disease (IBD) and Celiac disease which have such a profound effect on sufferers.”Professor Graham Lord, co-senior author on the study and Director of the NIHR BRC at Guy’s and St Thomas’ and King’s College LondonTweet
Co-senior author Dr Richard Jenner (UCL Cancer Institute) said: “Understanding how our DNA influences our risk of developing specific diseases is the key to developing precision therapies for the most severe illnesses. While there is still a great deal of work to be done before this work results in new treatments for patients, it is a significant breakthrough.”
Inflammatory bowel disease (IBD) alone affects 240,000 people in the UK and costs the NHS £700 million every year. It causes debilitating symptoms, impaired quality of life and serious complications including cancer, bowel blockage and bowel perforation. Many patients will be hospitalised and some will need to undergo disfiguring operations.
This study was supported by grants awarded by the NIHR BRC at Guy’s and St Thomas’ NHS Foundation Trust and King’s College Lodnon, Wellcome Trust, the Medical Research Council and the Biotechnology and Biological Sciences Research Council (BBSRC).